**FOI Ref: 6499**

**Category(ies): Clinical - Drugs**

**Subject: Diffuse Large B Cell Lymphoma (DLBCL)**

**Date Received: 14/07/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| Could you please answer the following questions? |
| 1. Does your trust treat patients with Diffuse Large B Cell Lymphoma (DLBCL)? If not, then which trust do you refer DLBCL patients to?
 | Yes |
| 1. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL)?
 | 15 |
| 1. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:
* R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
* R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
* Other immuno-chemotherapy
* Other chemotherapy
* Stem cell transplant or bone marrow transplant (autologous or allogeneic)
* Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - any line of treatment
* Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - third-line treatment only
* Tisagenlecleucel
* Axicabtegene ciloleucel
* Lisocabtagene maraleucel
 | R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)- 8 Patients* R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)- 3 Patients
* Other immuno-chemotherapy
* Other chemotherapy 4 Patients
* Stem cell transplant or bone marrow transplant (autologous or allogeneic) 0 Patients
* Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - any line of treatment 0 Patients
* Pola-BR (polatuzumab vedotin with rituximab and bendamustine) - third-line treatment only- 0 Patients
* Tisagenlecleucel- 0 Patients
* Axicabtegene ciloleucel- 0 Patients
* Lisocabtagene maraleucel- 0 Patients
 |
| 1. In the last 6 months, how many Diffuse Large B Cell Lymphoma (DLBCL) patients have you referred to other trusts for:
* Stem cell transplant or bone marrow transplant (autologous or allogeneic)
* CAR-T therapy (Tisagenlecleucel, Axicabtegene ciloleucel, Lisocabtagene maraleucel)
 | * Stem cell transplant or bone marrow transplant (autologous or allogeneic) 1 patient
* CAR-T therapy (Tisagenlecleucel, Axicabtegene ciloleucel, Lisocabtagene maraleucel) 1 patient
 |
| 1. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part?
 | No |